Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
August 12, 2021 16:01 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra...
Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
July 28, 2021 06:55 ET
|
Myovant Sciences, Inc.
First fiscal quarter 2021 total revenues of $41.1 million; net product revenue from U.S. sales of ORGOVYX® of $10.5 million and MYFEMBREE® of $1.1 millionMYFEMBREE approved by the U.S. FDA in May 2021...
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
July 20, 2021 02:00 ET
|
Myovant Sciences, Inc.
RYEQO is the first and only once-daily long-term treatment for uterine fibroids in EuropeIndication has no limitation for duration of use, as supported by safety and efficacy data from the Phase 3...
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
July 14, 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant Sciences to Present at Upcoming Investor Conferences
June 01, 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, June 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public...
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
May 26, 2021 16:15 ET
|
Myovant Sciences, Inc.
In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from...
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
May 21, 2021 08:30 ET
|
Myovant Sciences, Inc.
CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroidsGedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in...
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
May 11, 2021 06:58 ET
|
Myovant Sciences, Inc.
Fourth fiscal quarter 2020 total revenues of $24.6 million; net product revenue from sales of ORGOVYX in the U.S. of $3.6 millionFDA review of New Drug Application for relugolix combination tablet for...
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
May 04, 2021 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, May 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
April 12, 2021 06:58 ET
|
Myovant Sciences, Inc.
SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 yearsContraceptive...